INC Research Appoints Gregory M. Hockel, PhD to Lead Regulatory Consulting Practice
(Thomson Reuters ONE) -
Provides global leadership for group guiding Company's biopharmaceutical
customers through regulatory approvals worldwide
Raleigh, N.C., Nov. 18, 2013 - INC Research, a therapeutically focused global
clinical research organization (CRO) with a Trusted Process® for delivering
reliable results, today announced the appointment of Gregory M. Hockel, PhD, as
Senior Vice President, Regulatory Consulting. Based in Maryland near the FDA
headquarters, Dr. Hockel will leverage his extensive regulatory expertise to
lead the Company's global Regulatory Consulting organization. His team will be
responsible for assisting customers with product development and regulatory
approvals worldwide.
"Greg is an exceptionally experienced regulatory expert with more than three
decades of thought leadership in the pharmaceutical industry," said Alistair
Macdonald, Chief Operating Officer. "He has overseen the submission of more than
150 INDs and consulted on more than 40 NDAs/BLAs/CTDs. His expertise increases
our ability to look across the strategic plans of our customers and advise them
on the best regulatory strategies for gaining approval. The addition of Greg to
our already strong team increases the strategic regulatory insights INC Research
can offer to our customers."
Prior to joining INC Research, Dr. Hockel spent more than 14 years in senior
positions with inVentiv Health Clinical (formerly PharmaNet). He holds a
doctorate in physiology from the Indiana University School of Medicine and his
training also includes a postdoctoral fellowship with the University of
Mississippi School of Medicine Department of Physiology and Biophysics. Dr.
Hockel also holds a master's degree in business administration from the
Rensselaer Polytechnic Institute. He is active in multiple professional
organizations, including the Drug Information Association (DIA) and the
Association of Clinical Research Organizations (ACRO), and is an accomplished
speaker and author, contributing his expertise to a wide array of industry
conferences and trade publications.
With a network of global locations and on-the-ground expertise in all key
markets, INC Research is committed to delivering superior regulatory services to
help customers design the most efficient product development programs. The
Company supports customer needs across the entire product lifecycle, from early
regulatory development strategy consultations (FDA/Scientific Advice meetings)
to clinical trial and marketing authorization submissions and post-licensing
support. INC Research's service portfolio ranges from new chemical entities
(NCEs) to biologics, biosimilars, well-established substances (505(b)(2)
pathway), generic drugs, devices and in vitro diagnostics. For more information
on INC Research's Regulatory Consulting services, please visit the online
Resource Library.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development
programs of the highest integrity. Pharmaceutical and biotechnology companies
look to us for a complete range of customized Phase I to IV programs in
all therapeutic areas and patient populations. Our Trusted Process® methodology
and therapeutic foresight lead customers to better-informed product development
decisions, while our solid site relationships are a critical success factor in
delivering clinical trial results on time and on budget. INC was ranked "Top
CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site
Relationship Survey. INC Research is headquartered in Raleigh, NC. For more
information, please visit www.incresearch.com or follow us at (at)inc_research.
Contact: Lori Dorer, Media +1 (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1743748]
Unternehmensinformation / Kurzprofil:
Datum: 18.11.2013 - 15:56 Uhr
Sprache: Deutsch
News-ID 317773
Anzahl Zeichen: 4696
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Appoints Gregory M. Hockel, PhD to Lead Regulatory Consulting Practice"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
